Neutrophil/lymphocyte ratio: a potential biomarker in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
| Title: | Neutrophil/lymphocyte ratio: a potential biomarker in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors. |
|---|---|
| Authors: | Caterino M; Oncology Unit, Casa di Cura Villa Salus, Messina, Italy.; Lo Giudice G; Department of Medicine and Surgery, University of Enna 'Kore', Enna, Italy.; Damiano V; Clinical Department of Oncology and Hematology, University of Naples 'Federico II', Naples, Italy.; Perri F; Istituto Nazionale Tumori Di Napoli, IRCCS 'G. Pascale', Naples, Italy.; Giordano G; Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.; Ciardiello D; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Milan, Italy.; Mirabile A; Department Unit of Oncology, Medical Oncology Department, IRCCS San Raffaele Scientific Institute, Università Vita-Salute, Milano, Italy.; Pirozzi M; SCDU Oncologia, Ospedale Maggiore della Carità, Novara, Italy.; Sponghini AP; SCDU Oncologia, Ospedale Maggiore della Carità, Novara, Italy.; Ricci V; Medical Oncology Unit, AORN 'San Pio', Benevento, Italy.; Montella L; Oncology Operative Unit, 'Santa Maria delle Grazie' Hospital, ASL Napoli 2 NORD, Pozzuoli, Italy.; Addeo R; Oncology Division, Ospedale 'San Giovanni di Dio', Frattamaggiore, Italy.; Vignani F; Medical Oncology, Mauriziano Hospital, Turin, Italy.; Famiglietti V; Precision Medicine Department, Medical Oncology, University of Campania 'Luigi Vanvitelli', Naples, Italy.; Farese S; Precision Medicine Department, Medical Oncology, University of Campania 'Luigi Vanvitelli', Naples, Italy.; Di Lorenzo S; Precision Medicine Department, Medical Oncology, University of Campania 'Luigi Vanvitelli', Naples, Italy.; Ciardiello F; Precision Medicine Department, Medical Oncology, University of Campania 'Luigi Vanvitelli', Naples, Italy.; Fasano M; Precision Medicine Department, Medical Oncology, University of Campania 'Luigi Vanvitelli', Naples, Italy. |
| Source: | Frontiers in oncology [Front Oncol] 2025 May 06; Vol. 15, pp. 1557652. Date of Electronic Publication: 2025 May 06 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| Abstract: | Introduction: Literature has shown that there is a correlation between increased circulatory inflammatory factors and negative prognosis, which can be evaluated through the using the neutrophil and lymphocyte ratio (NLR). The aim of this research is to investigate the predictive and prognostic role of the NLR in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients, treated with immunotherapy, and its correlation to the overall survival (OS), progression free survival (PFS) and objective response rate (ORR).; Methods: This multicentric study coordinated by the Oncology Unit of University of Campania "Luigi Vanvitelli", retrospectively analyzed data from 135 patients diagnosed with R/M HNSCC from 13 Italian oncological centers.; Results: Two groups were made using the median NLR value of 4.2. 71 patients (52.6%) had NLR>4 and 64 patients (47.4%) had NLR4 was significantly shorter than that of patients with NLR4 and NLR |
| Competing Interests: | The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. |
| References: | Acta Oncol. 2021 Jun;60(6):704-713. (PMID: 33586577); Front Immunol. 2024 Jul 08;15:1416751. (PMID: 39040095); Bratisl Lek Listy. 2001;102(1):5-14. (PMID: 11723675); J Immunother Cancer. 2018 Aug 31;6(1):84. (PMID: 30170629); Br J Cancer. 2015 Jun 9;112(12):1904-10. (PMID: 26010413); Sci Rep. 2016 Feb 25;6:22089. (PMID: 26912340); J Natl Cancer Inst. 2014 May 29;106(6):dju124. (PMID: 24875653); Cancer Res Treat. 2021 Jul;53(3):671-677. (PMID: 33285051); Clin Pharmacol Ther. 2010 Apr;87(4):504-8. (PMID: 20147899); Oncologist. 2011;16(1):5-24. (PMID: 21212434); J Clin Oncol. 2010 May 10;28(14):2452-9. (PMID: 20368546); N Engl J Med. 2016 Nov 10;375(19):1856-1867. (PMID: 27718784); Int J Mol Sci. 2019 Sep 26;20(19):. (PMID: 31561442); Clin Cancer Res. 2010 Dec 1;16(23):5805-13. (PMID: 20956618); World J Urol. 2020 Jan;38(1):103-109. (PMID: 30953141); JAMA Netw Open. 2022 Apr 1;5(4):e227567. (PMID: 35426920); Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230); BMC Cancer. 2020 Dec 7;20(1):1206. (PMID: 33287745); Crit Rev Oncol Hematol. 2012 Jun;82(3):296-309. (PMID: 21798756); Otolaryngol Head Neck Surg. 2025 Feb;172(2):548-555. (PMID: 39675043); Carcinogenesis. 2015 Oct;36(10):1085-93. (PMID: 26354776); Int J Cancer. 2014 May 15;134(10):2403-13. (PMID: 24122750); J Clin Oncol. 2011 Jun 1;29(16):2199-205. (PMID: 21519009); Am J Hematol. 2010 Nov;85(11):896-9. (PMID: 20842639); Biomedicines. 2021 Aug 19;9(8):. (PMID: 34440249); Br J Cancer. 2019 Apr;120(7):714-727. (PMID: 30808992); Oncol Rep. 2023 Dec;50(6):. (PMID: 37859591); CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. (PMID: 25559415); BMC Cancer. 2017 Nov 10;17(1):744. (PMID: 29126400); Onco Targets Ther. 2015 Sep 29;8:2731-8. (PMID: 26491346); Cancers (Basel). 2022 Jan 18;14(3):. (PMID: 35158740); Crit Rev Oncol Hematol. 2016 Feb;98:242-53. (PMID: 26616525); J Clin Oncol. 2004 Aug 15;22(16):3408-19. (PMID: 15199089); Clin Lab Med. 2005 Dec;25(4):809-25, viii. (PMID: 16308094); Clin Exp Med. 2023 Sep;23(5):1551-1561. (PMID: 36401744); Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6. (PMID: 19318937); JAMA Otolaryngol Head Neck Surg. 2023 Jan 1;149(1):91-92. (PMID: 36394852); Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945); Medicine (Baltimore). 2018 Jul;97(30):e11446. (PMID: 30045267); Head Neck. 2018 May;40(5):1091-1100. (PMID: 29356179); Lancet. 2014 Mar 1;383(9919):816-27. (PMID: 24054424); PLoS One. 2016 Apr 27;11(4):e0154501. (PMID: 27119991); J Cancer Res Clin Oncol. 2023 Dec;149(20):18215-18240. (PMID: 38078963); Lancet. 2001 Feb 17;357(9255):539-45. (PMID: 11229684); Eur J Cancer. 2011 Nov;47(17):2633-41. (PMID: 21724383); J Support Oncol. 2007 Apr;5(4):157-62; discussion 164-6, 183. (PMID: 17500503); Cancer Immunol Immunother. 2023 Oct;72(10):3337-3347. (PMID: 37486396); Int J Cancer. 2011 May 1;128(9):2240-1. (PMID: 20602341); Breast Cancer. 2020 Sep;27(5):982-988. (PMID: 32306184); Sci Rep. 2016 Aug 11;6:31394. (PMID: 27510632); J Pers Med. 2023 Sep 19;13(9):. (PMID: 37763165); Exp Hematol Oncol. 2024 Aug 6;13(1):80. (PMID: 39107856); Breast Cancer Res. 2017 Jan 5;19(1):2. (PMID: 28057046); Medicina (Kaunas). 2022 May 17;58(5):. (PMID: 35630083); Cancer Rep (Hoboken). 2025 Feb;8(2):e70147. (PMID: 39933936); PLoS One. 2014 Mar 18;9(3):e92079. (PMID: 24642859); Curr Oncol. 2022 Aug 31;29(9):6277-6286. (PMID: 36135062); Lung Cancer. 2017 Apr;106:1-7. (PMID: 28285682); Sci Rep. 2018 Jun 21;8(1):9453. (PMID: 29930287); Ann Surg Oncol. 2013 Nov;20(12):3961-8. (PMID: 23838920); CA Cancer J Clin. 2013 Jan;63(1):11-30. (PMID: 23335087); Biomedicines. 2024 Sep 12;12(9):. (PMID: 39335592) |
| Contributed Indexing: | Keywords: HNSCC; ICI; NLR; immunotherapy; immunotherapy biomarkers |
| Entry Date(s): | Date Created: 20250521 Latest Revision: 20250522 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12088949 |
| DOI: | 10.3389/fonc.2025.1557652 |
| PMID: | 40395331 |
| Database: | MEDLINE |
Journal Article